Overview

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-30

Target enrollment:

Participant gender:

Summary

This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.

Phase:

PHASE1

Details

Lead Sponsor:

Shenzhen Majory Biotechnology Co., Ltd.

Treatments:

Injections